Biohackr: Track your protocol. Model the curve.

Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.

Overview

PT-141 (generic name bremelanotide, brand name Vyleesi) is a synthetic cyclic heptapeptide melanocortin receptor agonist developed by Palatin Technologies. It is FDA-approved (June 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of only two FDA-approved drugs for female sexual dysfunction (the other being flibanserin/Addyi). The approval followed two identical Phase 3 randomized controlled trials (RECONNECT) enrolling 1,267 premenopausal women and more than a decade of earlier development by Palatin.

PT-141 occupies a distinctive position among research peptides in this library: it has full FDA approval (similar to tesamorelin, semaglutide, and the other approved compounds), but is widely used off-label, particularly by men for erectile dysfunction, by postmenopausal women, and through compounding pharmacies for various indications. The off-label uses lack the Phase 3 evidence base supporting the approved indication.

The compound has a notable origin story: PT-141 was developed from Melanotan II (a broader melanocortin receptor agonist originally investigated for skin tanning). During early Melanotan II research, investigators observed unexpected pro-sexual effects in study participants: increased sexual arousal and spontaneous erections in men. Palatin pivoted to developing a related peptide specifically for sexual dysfunction, which became PT-141/bremelanotide.

The mechanism is fundamentally different from PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis): PDE5 inhibitors work peripherally on blood flow in genital tissue; PT-141 works centrally through melanocortin receptors (MC3R, MC4R) in the brain; the two mechanisms are complementary: PT-141 may help in cases where PDE5 inhibitors fail because the issue is desire rather than erectile function.

Forms

Available forms & half-lives

Form	Approximate half-life
Subcutaneous PT-141 (Vyleesi autoinjector, FDA-approved)	~2 hours
Subcutaneous PT-141 (compounded/research chemical)	~2 hours
Intranasal PT-141 (NOT FDA-approved, abandoned for BP concerns)	Variable; higher peak concentrations

What it does

Main effects

FDA-approved for premenopausal HSDD: Vyleesi approved June 2019 (NDA 210557); based on two identical Phase 3 RECONNECT trials enrolling 1,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder; statistically significant improvement on FSFI desire domain (effect size 0.49–0.61) and FSDS-DAO distress reduction
Central melanocortin receptor agonism: MC4R activation in hypothalamic paraventricular nucleus (PVN) is the primary mechanism for sexual desire effects; MC3R also contributes; triggers dopamine release in mesolimbic pathways and nitric oxide signaling in CNS
Addresses desire/arousal rather than peripheral vascular function: fundamentally different mechanism from PDE5 inhibitors (sildenafil, tadalafil); works centrally on motivation circuits rather than peripherally on genital blood flow
Off-label male erectile dysfunction (Phase 2 evidence): Safarinejad and Hosseini 2008 demonstrated 34% response rate in PDE5 non-responders vs 9% placebo; no Phase 3 male approval but off-label use is widespread; particularly relevant when PDE5 inhibitors fail
Off-label postmenopausal women: Excluded from FDA approval but mechanism is not estrogen-dependent; limited Phase 2 evidence; off-label use occurs
Approved Vyleesi protocol: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity, maximum 1 dose per 24 hours, maximum 8 doses per month, discontinue after 8 weeks if no benefit
Pre-filled autoinjector (FDA-approved Vyleesi) provides quality assurance and standardized dosing
Origin from Melanotan II research: initially observed pro-sexual effects in MT-II tanning studies led to development of PT-141 specifically for sexual dysfunction
Distinguishes from flibanserin (Addyi), the other FDA-approved HSDD treatment: different mechanism (PT-141 central MC agonism vs flibanserin serotonin modulation), different dosing (as-needed vs daily), different side effect profiles

What to watch for

Common side effects

Nausea (40% with first dose, diminishes with continued use to ~10–15%): most common adverse effect; often dose-limiting; central mechanism, not GI
Hyperpigmentation is a distinctive concern: MC1R activation on skin melanocytes causes skin darkening with repeated use; most prominent on face, breasts, and gums; cumulative effect with chronic dosing; may be permanent in some cases; FDA labeling specifically addresses this concern
Blood pressure elevation (transient, dose-related, peaks 2–4 hours post-injection) was the reason intranasal PT-141 was abandoned (higher peak concentrations produced more concerning BP elevations); contraindicated in uncontrolled hypertension per FDA labeling; concerning with established cardiovascular disease
Flushing (20–30%): generally mild and transient
Headache (~11%): generally mild and self-limited
Injection site reactions: pain, redness, swelling; generally mild
Coughing, fatigue, hot flashes, nasal congestion, paresthesias, vomiting: less common
Theoretical melanoma risk concern: given MC1R activation; no epidemiological signal documented but caution in melanoma history
Contraindicated: uncontrolled hypertension, established cardiovascular disease, pregnancy
Effect size is modest, not dramatic: FSFI desire domain effect size 0.49–0.61 is small-to-moderate; some patients respond well, others minimally; 8-week assessment appropriate per FDA label
FDA-approved indication is specific (premenopausal HSDD): off-label uses (male ED, postmenopausal women) lack equivalent Phase 3 evidence
Vyleesi is expensive and insurance coverage is often limited to the approved indication
Intranasal "PT-141 nasal spray" products are NOT FDA-approved: abandoned for BP concerns; higher peak concentrations = greater BP risk; users should be cautious
Compounded/research chemical PT-141 has variable quality, identity verification needed, often higher concentrations than approved Vyleesi
Not currently WADA-prohibited (verify before use in tested sport)

Key facts

Key facts worth knowing

PT-141 is a synthetic cyclic heptapeptide (7 amino acids in a cyclic structure) derived from alpha-melanocyte-stimulating hormone (α-MSH). The cyclic structure provides stability and receptor selectivity. Molecular weight 1025.18 Da (acetate form). Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.
FDA approval timeline: Original PT-141 development by Palatin Technologies from the 1990s onward; initial development as intranasal product showed blood pressure concerns; strategic pivot to subcutaneous and HSDD indication; RECONNECT Phase 3 trials in 1,267 premenopausal women; June 2019 FDA approval as Vyleesi for HSDD in premenopausal women (NDA 210557).
Mechanism is melanocortin receptor agonism: MC4R activation in hypothalamic paraventricular nucleus is the primary mechanism for sexual desire effects; MC3R also contributes; non-selective at MC1R, MC3R, MC4R, MC5R; triggers dopamine release and nitric oxide signaling in CNS; acts centrally rather than peripherally: fundamental distinction from PDE5 inhibitors.
RECONNECT Phase 3 trials (FDA-approval supporting): Two identical Phase 3 RCTs in 1,267 premenopausal women with HSDD, 24 weeks each; PT-141 1.75 mg SC vs placebo, as needed; primary endpoints FSFI desire domain score and FSDS-DAO distress score; effect size 0.49 to 0.61 on FSFI desire domain (modest but statistically significant); documented safety profile including nausea (40% first dose), blood pressure changes, hyperpigmentation.
Approved dose (Vyleesi): 1.75 mg subcutaneously as needed; at least 45 minutes before sexual activity; maximum 1 dose per 24 hours; maximum 8 doses per month; discontinue if no benefit after 8 weeks.
Off-label use is extensive: Male erectile dysfunction (especially PDE5 non-responders; Safarinejad and Hosseini 2008 showed 34% response with PT-141 vs 9% placebo); postmenopausal women (excluded from approved label); various sexual dysfunction presentations.
Hyperpigmentation is a unique concern: Melanocortin receptor activation affects skin melanocytes (MC1R); repeated dosing can produce darkening of skin, particularly face, breasts, gums; more prominent with higher cumulative doses; FDA labeling specifically addresses this concern; reversible with discontinuation in most cases.
Blood pressure effects: Transient elevation in BP after dosing; dose-related; concern with cardiovascular disease; contraindicated in uncontrolled hypertension. WADA status: Not currently on the WADA Prohibited List (verify current status before use in tested sport).

Legal status